Vascular dysfunction is increasingly recognized as a key contributor to the development of Alzheimer’s disease (AD) and alterations in brain perfusion are known to be present long before the clinical symptoms of AD develop, perhaps even preceding amyloid-beta plaque accumulation, tau protein deposition, and brain atrophy. We are investigating the most promising, noninvasive cerebrovascular imaging biomarkers that are sensitive and specific to the cerebrovascular alterations that occur in AD in its early stages.